Valeant Pharmaceuticals International, Inc. (VRX)
(Real Time Quote from BATS)
$23.40 USD
-0.83 (-3.43%)
Updated Jul 13, 2018 04:00 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Bausch Health Cos Inc. [VRX]
Reports for Purchase
Showing records 1 - 20 ( 133 total )
Company: Bausch Health Cos Inc.
Industry: Medical - Drugs
ValuEngine Detailed Valuation Report for VRX
Provider: ValuEngine, Inc
Company: Bausch Health Cos Inc.
Industry: Medical - Drugs
Company: Bausch Health Cos Inc.
Industry: Medical - Drugs
Salix Division Enters LUCEMYRA Co-Promotion Agreement; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Bausch Health Cos Inc.
Industry: Medical - Drugs
DUOBRII Complete Response Letter Received; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Bausch Health Cos Inc.
Industry: Medical - Drugs
Debt Refinancing Continues; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Bausch Health Cos Inc.
Industry: Medical - Drugs
Company: Bausch Health Cos Inc.
Industry: Medical - Drugs
1Q 2018 Results Reported; Guidance Raised- Along With a Change of Name; Raising Target to $20
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Bausch Health Cos Inc.
Industry: Medical - Drugs
1Q18 Results Slated for May 8; PLENVU PDUFA Date May 13; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Bausch Health Cos Inc.
Industry: Medical - Drugs
Company: Bausch Health Cos Inc.
Industry: Medical - Drugs
Company: Bausch Health Cos Inc.
Industry: Medical - Drugs
Company: Bausch Health Cos Inc.
Industry: Medical - Drugs
Further Debt Refinancing; Branded Franchise Execution Continues; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Bausch Health Cos Inc.
Industry: Medical - Drugs
4Q and FY2017 Financial Results Reported; 2018 Likely a Trough Year; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Bausch Health Cos Inc.
Industry: Medical - Drugs
Updating Revenue Estimates for 2018; Reiterate Neutral; Adjusting Price Target to $18
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Bausch Health Cos Inc.
Industry: Medical - Drugs
Company: Bausch Health Cos Inc.
Industry: Medical - Drugs
Insider Trading Settlement Deemed Approvable; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Bausch Health Cos Inc.
Industry: Medical - Drugs
Pipeline Maturation and Debt Repayments Bolster Progress; Raising Price Target to $24
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R